Delineatingthe Transcriptional Mechanisms in Immunity behind Allergy and Asthma: Milestones and Challenges Ahead
Pierre Cauchy*
Department of Cellular and Molecular Immunology, Max Planck Institute of Immunobiology and Epigenetics, Stübeweg, Freiburg, Germany
*Corresponding author:Pierre Cauchy,Departmentof Cellular and Molecular Immunology, Max Planck Institute, Germany.Tel: +4907615108730; E-Mail:cauchy@ie-freiburg.mpg.de
Received Date: 27 May, 2017; Accepted Date: 19 June, 2017; Published
Date: 27June, 2017
Citation: Cauchy P (2017) Delineating the Transcriptional Mechanisms in Immunity behind Allergy and Asthma: Milestones and Challenges Ahead. Int J Allergy Asthma 2017: J101. DOI: 10.29011/IJAA-101. 100001
1. Abstract
Allergy and asthma have roots in imbalances in immune cell homeostasis,
namely a shift towards T-helper 2(Th2)-driven
increases of Immunoglobulin E (IgE) immunity. Here, we describe the
transcriptional processes that lead to the emergence of the immunological
actors of allergy and asthma, i.e. Th2,
type 2 Innate Lymphoid Cells(ILC2), mast, IgE plasma and regulatory T-cells(Treg), as well as to the advent of imbalances
towards Th2 responses in pathological
cases. We review in detail the latest advances in terms of genome-wide
characterisation of the transcriptional landscapes of the protagonists of
allergy and asthma, both in normal and pathological contexts if available, as
well as a summary of current clinical approachesand discuss the requirement for
further functional-based genome-wide characterisation of mechanisms that can lead
to the attenuation of these conditions.
1. Introduction
The immune system is an amazingly adaptive piece of machinery that safeguards the integrity of the organism from attacks by pathogens. It is however not entirely error-proof; even if failsafe mechanisms exist to suppress abnormal immune reactions, mismanagement of the various factors involved in immune responses does occasionally give rise to immune disorders. While several of these conditions have been extensively characterised and thus make up the bulk of research in immunity due to their severity (e.g. auto-immune diseases, leukaemia and lymphoma), a number of disorders, such as allergic diseases and asthma generally affect a much higher proportion of the population, even if mortality rates are far lower for those[1.2]. Historically, following the discovery of histamine [3], its release during allergic responses was identified to occur via degranulation by mast cells [4], the most obvious mechanism underlying these pathologies. There is no single protagonist of allergy and asthma but multiple ones, which has resulted in the detailed study of the following cell types: classically mast cells, Immunoglobulin E (IgE)-secreting B-cells, Th2 cells[5], with the recent addition of type 2 Innate Lymphoid Cells (ILC2s)[6,7], whose function is related to Th2 cells[8]. Mast cells express the high-affinity receptor to IgE antibodies (fragment crystallisable epsilon receptor 1,FcεR1) [5], causing degranulation upon IgE Fc binding[9].Patients suffering from asthma and/or allergy present elevated serum IgE levels[10,11], thus increasing sensitivity towards the degranulation process. B-cell class-switch towards the IgEisotype is in turn positively affected by T-helper 2 (Th2) cytokines [12, 13]. Thus, allergy and asthma mostly result from imbalanced cross-talk within the Th2 response. In fact, allergy and asthma are generally regarded as early-acquired immune bias towards Th2 responses [14], whereby attempts have been made to restore the balance between Th1 and Th2 responses [15,16]. Further, while tolerance to antigens can normally be regulated by regulatory T-cells (Treg), however there has recently been increasing evidence that Treg fail to elicit adequateimmune suppression in certain allergies[17]. It thus becomes quickly apparent not only a comprehensive understanding of the how the interplay within the Th2 response becomes biased, but also to understand the origin of imbalances in the differentiation, proliferation and maintenance of its protagonists is key to develop treatments against allergic and asthmatic reactions.The emergence of the haemopoietic system and its actors is a tightly-controlled process whereby the timing and nature of epigenetic and transcriptional regulation is critical [18,19].Thus, to fully understand how allergies and asthma arise, i.e. via imbalance towards the Th2 response, the origin and specification of the cell types involved must be fully understood. Here, we review the transcriptional mechanisms that lead to the emergence of the main actors involved in allergy and asthma, i.e. Th2 cells, ILC2s, mast cells, IgE B-cells and Treg, as well as within the framework of modern transcriptional regulation. We also describe current treatment approaches and further discuss possible challenges and research directions, notably using inhibitor treatments coupled with genome-wide characterisation of transcriptional landscapes of the actors of allergy and asthma.
1.1. Th2 Cells: TheSubstrate for Allergy and Asthma
Th2 cells represent the
cornerstone of humoral immune responses. Once naïve CD4+ T-cells (Th0)
are activated via antigen presentation via the Major Histocompatibility II Complex (MHCII) on the T-cell
receptor and CD3, T-cells can differentiate towards the following T-helper types: Th1, involved in cell-mediated responses;Th17, related to Th1
but involved in the control of inflammation, extracellular pathogens and
pathogen clearance; Th2, involved in
humoral-mediated responses; Th9, related
to Th2, involved in defence against
helminths; Treg or memory T-cells[20]. Importantly, Th2s
secrete interleukin 4(IL-4),
IL-5, IL-6, IL-13 and recruit IgE
B-cells, mast cells and eosinophils[12](Figure 1).This
feature makes Th2cells critical playersin allergic and asthmatic
reactions. As there is evidence for a bias favouring Th2 responses over Th1
in allergy and asthma[14], attempts have been
made at restoring Th1 responses[15,16]. Differentiation
towards Th2 is driven via IL-4, while
IL-12 drives Th1 differentiation [21].IL-4 is known to downregulate Th1 differentiation[22]. As a result, Th2 cytokines as well as chemokines
are higher in allergy and asthma patients [12,23]
with Th2 cell counts reportedly higher [24]. On the
other hand, interferon gamma, which is secreted by Th1 cells, downregulates Th2 responses[25].
IL-4 and IL-5 also specifically prime mast cells for
different profiles of IgE-dependent cytokine production[26].Importantly,
ILC2s also express the IL-33 receptor, which drives the production of Th2 cytokines [27].
In Th2 cells, at the transcriptional level, the hallmark Th2Transcription Factor (TF) GATA binding protein 3(GATA3)outcompetes T-box protein expressed in T cells(T-bet), the defining Th1 TF[28]. Other hallmark TFs for Th2 cells are Signal Transducer and Activator of Transcription 6(STAT6) and Interferon Regulatory Factor 4 (IRF4), while STAT4 expression characterises Th1 cells[21,29]. However, there are signs that priming towards either cell-type already exists in freshly activated T-cells[30].Since Th2 cells have been long described and due to their abundant cell counts, Th2 differentiation has been comprehensively characterised at the transcriptional level, more recently using high-throughput sequencing: characterisation of binding patterns of hallmark TFs (T-bet;GATA3; IRF4;basic leucine zipper transcription factor ATF-like,BATF) has been performed via ChromatinImmune Precipitation Sequencing (ChIP-Seq) in during the last decade[31,34]. Gene expression profiling using RNA Sequencing (RNA-Seq) has also shed light on the full extent of genes characterising Th2 signatures[35,36], notably at the single-cell level[37,38]. More recently, a RNA-Seq study performed on Th2 cells involved in allergic airway inflammation demonstrated that Th2 activity and survival is regulated by IL-10[39], further pointing asan important role for Treg in these pathologies. Further, chromatin accessibility profiling was also performed in Th2 cells usingDNase I hypersensitive site Sequencing(DNAse-Seq) and Assay for Transposase-Accessible Chromatin Sequencing (ATAC-Seq)[34,40]. Single cell assays studying Th0 to Th1 and Th2 transitions have also been performed[37,38]. Certain histone modification ChIP-Seq assays performed in Th2 cells from asthmatic and healthy also revealed regulatory elements linked with asthma susceptibility[41].
1.2. ILC2s: The New Allergy and Asthma Players in Town
ILC2s represent a relatively newly-described type of innate immune cells: their discovery resulted into a new class of innate lymphocytes, ILCs, now encompassing Natural Killer(NK) cells. Lacking Recombination-Activating Gene (Rag) 1 and 2 expression, they do not rearrange or express the T-cell receptor. If an analogy can be made, ILCs are the innate equivalent of cytotoxic and helper T-cells, except that their function is antigen-independent. The analogy also extends to Th cells, with ILC1s displaying features similar to Th1, notably T-bet expression, while GATA3 was shown to be essential for ILC2 function[42,43], conferring ILC2s a function related to Th2[8]. As for Th2, ILC2s express and require STAT6 andT-Cell Factor 1 (Tcf1)[44,45]. The typical ILC2 markers are CD25, CD117, Inducible T-cell Co-Stimulator (ICOS), CD161, prostaglandin D2 receptor 2 (CRTH2), and GATA3[46]. ICOS activation was recently shown to be required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyper reactivity [47].ILC2s also express the IL-7 receptor and their survival and proliferation may require STAT5 function[47].Importantly, ILC2s also express the IL-33 receptor [27]. Thus, as for Th2, they are equally as important for the onset of allergy and asthma as they secrete IL-4,5,9,13(Figure 1).In fact, they were shown to be critical for the initiation of adaptive Th2cell-mediated allergic lung inflammation[48].In Rag2-deficient mice, ILC2s can induce allergy alone[49], reviewed in [50], being able to produce very high amounts of IL-5 and IL-13 [51].
Understanding the transcriptional regulation events that lead to ILC2 should thus be at the centre of current efforts, especially given that they can produce copious amounts of IL-5 and IL-13. A question remains as to whether attempts to downregulate Th2 responses in favour of Th1 ones also affect ILC2s. Recently, genome-wide screens have been performed: mapping of chromatin accessibility revealed convergent regulomes between ILC2s and Th2 cells[34]. Other efforts, including genome-wide mapping of GATA3 in ILC2s and ILC3s, showed that while this TF is essential for ILC2 function, ILC3s also continuously require GATA3 expression after commitment, albeit at low levels[43]. Further, single-cell RNA-Seq assays have demonstrated the heterogeneity that exists in the transcriptomes of ILCs, including ILC2s [52,53].
1.3. Mast Cells: The Main Effector of Allergy and Asthma
Mast cells are the main effector cell type of allergy and asthma. They are myeloid cells derived from Common Myeloid Progenitors (CMP)or Granulocyte-Macrophage Progenitors (GMP), evolving into Basophil/Mast Cell Progenitor (BMCP)and ultimately mast cells. Beside the high-affinity IgE receptor that causing degranulation upon IgE Fc binding [5,9](Figure 1), mast cells also express receptors to cysteinyl leukotrienes [54]. Generally, the transcriptional activators needed for mast cell differentiation have been well characterised, mostly using single locus assays[55]. Mast cell differentiation is dose-dependent on correct Purine-Rich 1 (PU.1) and CCAAT-Enhancer-Binding Protein Alpha (C/EBPα) levels and requires for expression [56,57], a general trait of normal myeloid differentiation [58]. Activator Protein 1 (AP-1)is also required for the degranulation process[59]. Upstream Transcription Factor 2, c-Fos interacting (USF2) was also showed to play a critical role in driving mast cell differentiation [60].Gata1 deletion impairs mast cell differentiation [61], although this process can be rescued[62], except in skin and the stomach [63]. E74-like ETS Transcription Factor 1(ELF1) and GATA1 were also shown to bind to tissue-specific enhancers elements of human high-affinity IgE receptor alpha-chain gene [64]. STAT3 and Melanogenesis Associated Transcription Factor (MITF) cooperation was also to be critical in mast cell development [65].Importantly, IL-33 is produced by mast cells and regulates IgE-dependent inflammation [66]. Further, besides the high-affinity FcεRI receptor[5], low-affinity IgG receptors can also induce IgE-mediated degranulation in mast cells [67].STAT5 expression is required for IgE-mediated mast cell function including degranulation [68]. STAT6, a mediator of Th2 immunity, is also expressed in mast cells [44]. From a pathological standpoint, asthmatic patients present enhanced degranulation of mast cells [69], and furthermore Th2 cytokines such as IL-5 are critical for the mobilisation of mast cells in airways [70].Importantly, mast cells express IL-33 as well as its receptor [27]. IL-33 appears to be critical for the development of asthma at a young age, as it was shown to promote type 2 immunity in the developing lung, with local accumulation of Th2 cells [71].
At the genome-wide level however, characterisation of transcriptional regulation in mast cells remains scarce, even though one study comprehensively mapped binding of key mast TFs such as ETS-Related gene (Erg), Finkel-Biskis-Jinkins murine osteogenic sarcoma virus transforming gene (Fos), MITF, transcription factor E2-Alpha (E2A), Stem-Cell Leukaemia (Scl), GATA2, Friend Leukaemia Integration 1 (Fli1), LIM domain only 2 (Lmo2), Runt-Related Transcription Factor 1 (Runx1) and myeloid ecotropicviral integration site 1 homolog(Meis1)[57].Importantly, within the framework of allergy and asthma, early gene expression microarray assays identified mast cells as a source of IL-11 [72], as well as upregulation of chemokine genes [73].A more recent study using RNA-Seqcarried out in human mast cells stimulated by IgE or FcεRI-aggregation pointed to a complex network of genes involved in inflammatory responses [74]. More recent studies using Cap Analysis Gene Expression Sequencing (CAGE-Seq) have also increased the resolution of our knowledge of mast cell gene expression patterns [75].
1.4. IgEB-Cells: Which Factors Drive Proliferation?
IgE B-cell, like all mature B-cells, are derived from IgM-expressing immature B-cells that have undergone Class-Switch Recombination (CSR) in the germinal centre, following initial VDJ recombination of the heavy chain starting in pro B-cells and completing bythe pre-B-cell stage(Figure 1). For IgE isotypes, CSR results in the excision of chains up to the ε chain. CSR to the IgE isotype also requires germline transcription from the promoter [76]. Polymorphism of these isotypes is enhanced by Activation-Induced Cytidine Deaminase (AID)-induced Somatic Hypermutations (SHM), a process which generates mutations of C-G pairs via deamination at the DNA level. AID is also essential for CSR. There is controversy whether Inhibitor of DNA binding 2 (Id2) inhibition of CSR and SHM [77]is involved in the down regulation of IgEisotope generation[78,79] as Id2-deficient mice exhibit enhanced CSR to IgE[80], which points to the importance of this inhibitor in allergy and asthma. However, in normal conditions, E (IgE) isotype antibodies are normally present at low levels in the plasma and are mainly produced by plasma cells in the mucosal-associated lymphoid tissue [76]. As a result, these isotypes are the least abundant in healthy individuals[81].While even in allergic and asthmatic conditions, serum IgE remains low, as opposed to the rare hyper-IgE syndrome [82], there is evidence of elevated IgE production local to the nasal mucosa in asthma patients[83]. There is however indication that while serum IgE levels remain low, they are increased in allergic patients [12].In mechanistic terms,IgE CSR is directly influenced by Th2 cytokines [12,13,84]. IL‐ 4/IL‐13 and CD40 ligation are needed for IgE CSR [12,85]. B-cells also express the low-affinity FcεRIIIgE receptors (CD23) [5]. Further, it was shown that CD23 negatively regulates IgE CSR [86].
Transcriptional activation of the I€ promoter is achieved by binding of STAT6 and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB), which are induced by IL-4 and CD40 in this case, respectively, as well as PU.1, E2A, paired box protein 5 (PAX5) and CEBP [76].STAT5b also appears to influence IgE CSR, as Stat5b-deficient patients show increased serum IgE levels, as well as decreased CD8+ T cell number, and severe eczema[87,88]. The IgH locus also features two Matrix Attachment Regions (MARs) around the Eμ enhancer [89]. MARs confer permissive transcriptional conformations [89,90] and are bound by special AT-rich Sequence-Binding Protein (Satb) proteins, which, in T-cells, are required for the correct expression of the rearranged TCR chains [91,92]. In antibody-secreting B-cells, Satb1 is expressed, at least at the mRNA level [93]. Satb proteins might thus also represent the focus of transcriptional research in B-cells and more particularly in IgE-producing cells, coupled with chromosome capture conformation assays. It might be, as for other the initial recombination in other Igs, that each CSR towards the various isotypes, including IgE, requires a distinct, specialised chromatin structure [94].However, while histone modification patterns have been described in the IgE switch region in IgE cells using extensive ChIP-qPCR characterisation [95], to date, no wider-reaching endeavour has been attempted in these cells, neither using TF ChIP-Seq. Thus, the transcriptional landscape of IgE cells remains largely uncharacterised, even a recent study extensively characterised the transcriptional landscape of class-switching germinal centre B-cells, using ChIP-Seq, ATAC-Seq and RNA-Seq[96].
At the gene expression level, several characterisations have already been performed within the framework of allergy and asthma, at first using microarray technology, which uncovered extensive numbers of novel key genes involved in these pathologies, such as Bcl2 and IL-33 itself [97,100]. More recently, RNA-Seq from circulating CD19+ B-cells from allergic asthma patients also evidenced upregulation of the IL-4 receptor [101]. Importantly, IgE repertoire sequencing also highlighted more apparent changes in IgE repertoires in patients with allergic rhinitis[102].B-cell single-cell RNA-Seqwas also recently performed in the model lymphoblastoid cell line GM12878 [103].
1.5. Treg: Cells that Can (Suppress Allergy and Asthma)
Treg have recently come at the centre of focus of research in allergy and asthma. These cells are derived from activated Th0 cells, and are characterised by intermediary CD25 expression as well as high forkhead Box P3 (FoxP3) expression[104]. Their main function consists of suppressing autoreactive T-cells, which is achieved by IL-10 and Transforming Growth Factor Beta (TGF-β) secretion(Figure 1). Recently, an allergen-suppressing Treg subtype has been uncovered, suggesting that the maintenance of these cells is important in combatting allergy and asthma via IL-10-mediated suppression of allergenic Th2 and IgE cells [39,105,106].Importantly, Treg can also suppress ILC2 cells[107]. However, there are also hints of a defective Treg response in allergy and asthma [108]. Further, in those pathological conditions, the balance between Th2/Treg populations is shifted towards Th2 cells, resulting in less Tregcells [109,110]. Artificially skewing the Th2/Tregratio towards a Th2 cell-like lineage via reprogramming of Tregwas also shown to impair oral tolerance and to promote food allergy [17]. The converse, which entailed reprogramming Th2 cells into Treg by exposure to TGF-β, all-trans retinoic acid and rapamycin, resulted in fully functional Treg able to suppress Th2-mediated airway hyperreactivity and allergen-dependent IgE secretion in allergic asthma [111]. The transcriptional landscape of Treg has been extensively characterised via high-throughput approaches hinging on factors critical Treg development, on histone modification status and RNA-Seq[33,112,113]. Recent genome-wide studies pertaining to tissue-resident Treg, also involved in allergy tolerance, showed that IRF4, BATF and, importantly, IL-33 are responsible for the development and maintenance of these cells [114]. These cells, which might fail to suppress allergenic T-cells, are thus also preserved in allergic pathologies, thereby contributing to their maintenance.
1.6. Current Clinical and Translational Approaches
Besides anti-histamine, anti-leukotriene, mast-cell stabiliser or bronchodilator -based approaches, several clinical approaches have been developed against allergy and asthma in the last 30 years, based on the increased physiological and transcriptional understanding of these pathologies.For example, anti-IgE monoclonal antibody treatments [115], reviewed in[116], have been used to treat allergic asthma for almost two decades, prompted by the discovery of elevated IgE levels in the nasal mucosa. Further, treatment with a CD23 transducing monoclonal antibody also reduces allergic pulmonary inflammation [117]. Importantly, the Phosphoinositide 3-Kinase(PI3K) pathway was also shown to be a negative regulator of IgE production [118], which may represent novel approaches. Against excessive Th2-based immunity, interferon gamma was importantly described as a potent allergy suppressor [119].For mast and Th2 cells, IL-33 was shown to play a key role at a young age[71]. Type-2 immunity thus appears to be mostly IL-33-dependent and not T- or B- cell dependent, hinting at a critical role for this axis and pointing to early treatments aiming to reduce IL-33 levels. The so-called “Hygiene Hypothesis”, whereby how excessive antiseptic sterility could potentially lead to reduced stimulation towards Th1 development, favouring Th2 development over Th1[76],has also led to original treatments, such as the use of farm dust and endotoxin to reduce lung epithelial cell allergy [120], indicating that, per se, the initial IL-33 boost in early age might not be an irreversible phenomenon. Current characterisation efforts of the IL-33 axis, notably at the transcriptional level, could thus give rise to further treatments aiming to reduce early-acquired Th2 sensitisation.Further, aiming to restore the Th2/Tregbalance [111]could also provide new treatment approaches, and thus warrant further characterisation of Treg differentiation at the transcriptional level.
1.7. The Need for Further Integrative,Functional and TranslationalStudies as well as in Novel Cell Types Involved in Allergy and Asthma
In this review, we have described current advances in the transcriptional understanding underlying allergy and asthma and a summary of current treatment approaches. For each of the key players in allergy and asthma, i.e. Th2 cells, ILC2 cells, mast cells, IgE B-cells and Treg, single-cell assays carried out in pathological conditions would be of great interest to understand how part of these cells get primed towards an allergic/asthmatic phenotype. For IgE B-cells, further characterisation is required to comprehend the upregulation of CSR that leads to this isotype. While single-cell B-cell RNA-Seq has been performed [103], the field of allergy and asthma would greatly benefit from such assays from patient cells, notably from the nasal mucosa where IgE production can be elevated in allergic reactions [83]. This would enable identifying how the differentiation trajectories of B-cells get skewed towards the IgE isotype, coupled with transcriptional assays such as ChIP-Seq and ATAC-Seq.Further, functional assays, used with current anti-IgE monoclonal antibody treatments in combination with genome-wide approaches would also shed light on the full effects and possible compensation mechanisms of these therapies. Further, a subtype of allergenic memory B-cells was recently identified as long-lived IgE producing plasma cells, at higher levels in patients with rhinitis [121]. Finally, a class of regulatory B-cells, secreting IL-10 similarly to Treg, was recently identified to modulate immunological tolerance by suppressing pro-inflammatory B- and T-cells [122]. These latest cell types could thus also represent the next focus of research at the transcriptional level in allergy and asthma. The germinal centre B-cell stage is also of particular importance, albeit limiting in cell numbers, as most studies on B-cell differentiation, e.g. Encyclopaedia of DNA Elements (ENCODE) genome-wide screens, were performed using immortalized cell lines often corresponding to later stages of differentiation using B-cells of isotypes other than IgE, and not plasma cell lines expressing IgE such as the U266 cell line[123], which could thus constitute a suitable model for such investigations to identify TFs involved in IgE CSR and SHM.
In mast cells, systematic characterisation of their transcriptional landscape is also still quite limited to a few TFs, while several more might be involved in allergy and asthma. Functional assays with in mast cells, such as with Mitogen-Activated Protein Kinase (MAPK) inhibitors, since AP-1 involved in degranulation, would shed further light on the transcriptional consequences of e.g. mast cell stabilisers. The importance of early exposure to the IL-33 axis in allergy and asthma [71] also hints at further research into approaches aiming to reduce IL-33 secretion by mast cells, thus warranting detailed transcriptional understanding of this geneand of its downstream effectors.
For ILC2s, Th2 and Treg cells, we have shown that there already exists extensive knowledge of the transcriptional landscape of these cells. Further, computational modelling has been used to model the Th0 to Th1/Th2/Th17/Treg differentiation in systems biology [124]. By modulating the expression of key genes in silico using allergic conditions, determining how to readjust the balance towards normal Th1/Th17/Treg differentiation could also pave the way to new mechanistic approaches. These approaches, coupled with genome-wide approaches, might be needed to obtain a comprehensive understanding of the full-complement of cell- and system-wide effects of pathway inhibitors used in current treatments for e.g. allergic or eosinophilic asthma, such as of the IL-4, IL-5, IL-13 axes [125,126], with already several drugs readily available, reviewed in [127]. Additionally, the relatively novel T-cell subclass, Th9, which express IL-9 and PU.1 [128], may also have a link to allergy and asthma, warranting further characterisation of these cells [129].Further, forTreg, single-cell genome-wide assays would help delineate the differentiation trajectories of Treg sub-populations, including those especially involved in suppressing allergenic Th2 cells, as well as those that fail to do so. Such assays could provide mechanistic insights that may develop into translational research in the long run. In ILC2 cells, carrying single-cell assays in pathological conditions should be of great benefit to the field to study the development of allergenic ILC2 cells.In addition, to date, ChIP-Seq assays involving TFs have yet to be performed using Th2 cells from allergy or asthma patients. This would be highly desirable to characterise the players involved in misregulation, notably to identify druggable targets, as the observed epigenome is often a direct consequence of TF binding [130], even though chromatin accessibility and histone modification status can also have a direct effect on TF binding [131]. Further, while single cell assays carried out in Th2 cells should allow giving insights into potential priming towards each cell fate [37,38], what would ideally need to be done is to perform such assays in an allergic/asthmatic context, i.e. from patient samples.
Finally, while there is evidence that some allergies can be B-cell
driven, several variables can influence which cell type is key to triggering
allergic responses[132]. This points towards the
need for co-culture and system-wide approaches. A wider-looking view on the
imbalances between cell types involved in allergy versus those that are not
might be required, notably using simple concepts, e.g. the so-called “hygiene
hypothesis”. Thus, mass-scale genome-wide gene screens including expression
data, such as the 100,000 genomes project [133]
would benefit the field if they were to include cell types involved in allergy
and asthma, and, combined with Genome-Wide Association Studies (GWAS) and hygiene,
pathogen exposure data worldwide would provide means of testing if e.g. the
hygiene hypothesis holds true.In any case, the field would also greatly benefit
from compendia such as the epigenome roadmap[134]
or ENCODE [135].
Figure 1: Summary of transcriptional actors involved in the differentiation of
effectors of allergy and asthma, and main interactions between immune cell
types via secretion of cytokines (shown in bold). Interactions favouring
allergy or asthma are shown in red; those inhibiting it are shown in green. Arrows
and blunt edges originating from cytokines indicate activation and inhibition;
respectively. CLP: Common Lymphoid Progenitor; ILC2: Innate Lymphoid Cell; Th:
T-helper; Ig: Immunoglobulin.
2.
Wheatley LM, Togias A (2015) Clinical practiceAllergic rhinitis. N Engl J
Med 372: 456-463.
13.
BarnesPJ (2001) Th2 cytokines and asthma: an introduction. Respir Res 2:
64-65.
14.
Berger A (2000) Th1 and Th2 responses: what are they? BMJ 321: 424.
16.
Jones CA, Holloway JA, Warner JO (2000) Does atopic disease start in
foetal life? Allergy 55: 2-10.
44. Walford HH, Doherty TA (2013) STAT6 and lung inflammation. JAKSTAT 2:
e25301.
82. Freeman AF, Holland SM (2008) The hyper-IgE syndromes. Immunol Allergy
Clin North Am 28: 277-291.
88. Kanai T, Jenks J, Nadeau KC (2012) The STAT5b Pathway Defect and
Autoimmunity. Front Immunol 3: 234.
100.Sordillo J, Raby BA (2014) Gene expression profiling in asthma. Adv Exp
Med Biol 795:157-181.
122.Rosser EC, Mauri C (2015) Regulatory B cells: origin, phenotype, and
function. Immunity 42: 607-612.